Esophageal disease in scleroderma

Journal of Clinical Gastroenterology

Volumn 40, Issue 9, 2006, Pages 769-775

  Ebert, Ellen C ^a,b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b MEB 478 ^*  (United States)

Author keywords

Esophagus; Reflux; Scleroderma; Systemic sclerosis

Indexed keywords

ANTACID AGENT; CALCIUM CHANNEL BLOCKING AGENT; CISAPRIDE; CYCLOFENIL; DILTIAZEM; HISTAMINE H2 RECEPTOR ANTAGONIST; METOCLOPRAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PROKINETIC AGENT; PROTON PUMP INHIBITOR;

BARRETT ESOPHAGUS; DISEASE ASSOCIATION; DYSPHAGIA; ESOPHAGUS CANDIDIASIS; ESOPHAGUS DISEASE; ESOPHAGUS MOTILITY; ESOPHAGUS MUSCLE; ESOPHAGUS PRESSURE; ESOPHAGUS STRICTURE; GASTROINTESTINAL DISEASE; HEARTBURN; HUMAN; LUNG DISEASE; MANOMETRY; MUSCLE ATROPHY; MYOFIBROSIS; PERISTALSIS; PH MEASUREMENT; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; SCLERODERMA; SYMPTOM; SYSTEMIC SCLEROSIS;

AUTONOMIC NERVOUS SYSTEM; DISEASE PROGRESSION; ESOPHAGEAL DISEASES; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; HUMANS; LIFE STYLE; LUNG DISEASES; MANOMETRY; SCLERODERMA, DIFFUSE;

EID: 33749414559     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000225549.19127.90     Document Type: Review

References (100)

1. Le Roy EC, Black C, Fleischemajer R, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol. 1988;15:202-205.
2. Kinder RR, Fleischman R. Systemic scleroderma: a review of organ systems. Int J Dermatol. 1974;13:362-395.
3. Abu-Shakra M, Guillemin F, Lee P. Gastrointestinal manifestations of systemic sclerosis. Sem Arthritis Rheum. 1994;24:29-39.
4. Marie I, Levesque H, Ducrotte P, et al. Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol. 2001;96:77-83.
5. Sridhar KR, Lange RC, Magyar L, et al. Prevalence of impaired gastric emptying of solids in systemic sclerosis: diagnostic and therapeutic implications. J Lab Clin Med 1998;132:541-546.
6. Bortolotti M, Turba E, Tosti A, et al. Gastric emptying and interdigestive antroduodenal motility in patients with esophageal scleroderma. Am J Gastroenterol. 1991;86:743-747.
7. McCallum RW, Berkowitz DM, Lerner E. Gastric emptying in patients with gastroesophageal reflux. Gastroenterology. 1981;80:285-291.
8. Wegener M, Adamek RJ, Wedmann B, et al. Gastrointestinal transit through esophagus, stomach, small and large intestine in patients with progressive systemic sclerosis. Dig Dis Sci. 1994;39:2209-2215.
9. Marie I, Levesque H, Ducrotte P, et al. Manometry of the upper intestinal tract in patients with systemic sclerosis: a prospective study. Arthritis Rheum. 1998;41:1874-1883.
10. Hamel-Roy J, Devroede G, Arhan P, et al. Comparative esophageal and anorectal motility in scleroderma. Gastroenterology. 1985;88:1-7.
11. Lock G, Zeuner M, Lang B, et al. Anorectal function in systemic sclerosis: correlation with esophageal dysfunction? Dis Colon Rectum. 1997;40:1328-1335.
12. Maddern GJ, Horowitz M, Jamieson CG, et al. Abnormalities of esophageal and gastric emptying in progressive systemic sclerosis. Gastroenterology. 1984;87:922-926.
13. Kaye SA, Seifalian AM, Lim SG, et al. Ischaemia of the small intestine in patients with systemic sclerosis: Raynaud's phenomenon or chronic vasculopathy? QJM. 1994;87:495-500.
14. Cohen S, Laufer I, Snape WJ, et al. The gastrointestinal manifestations of scleroderma: pathogenesis and management. Gastroenterology. 1980;79:155-166.
15. Treacy WL, Baggenstoss AH, Slocumb CH, et al. Scleroderma of the esophagus. A correlation of histologic and physiologic findings. Ann Int Med. 1963;59:351-356.
16. D'Angelo WA, Fries JF, Masi AT, et al. Pathologic observations in systemic sclerosis (scleroderma), a study of 58 matched controls. Am J Med. 1969;46:428-440.
17. Ling TC, Johnston BT. Esophageal investigations in connective tissue disease. Which tests are most appropriate? J Clin Gastroenterol. 2001;32:33-36.
18. Kaye SA, Siraj QH, Agnew J, et al. Detection of early asymptomatic esophageal dysfunction in systemic sclerosis using a new scintigraphic grading method. J Rheumatol. 1996;23:297-301.
19. Kemp Harper JA, Jackson DC. Progressive systemic sclerosis. Br J Radiol. 1964;38:825-834.
20. Orringer MB, Dabich L, Zarafonetis CJD, et al. Gastro-esophageal reflux in esophageal scleroderma: diagnosis and implications. Ann Thorac Surg. 1976;22:120-130.
21. Clements PJ, Kadell B, Ippoliti A, et al. Esophageal motility in progressive systemic sclerosis: comparison of cine-radiographic and manometric evaluation. Dig Dis Sci. 1979;24:639-644.
22. Zamost BJ, Hirschberg J, Ippoliti AF, et al. Esophagitis in scleroderma: prevalence and risk factors. Gastroenterology. 1987;92:421-428.
23. Weston S, Thumshirn M, Wiste J, et al. Clinical and upper gastrointestinal motility features in systemic sclerosis and related disorders. Am J Gastroenterol. 1998;93:1085-1089.
24. El-Serag H, Sonnenberg A. Association of esophagitis and esophageal strictures with diseases treated with nonsteroidal anti-inflammatory drugs. Am J Gastroenterol. 1997;92:52-56.
25. Katzka OA, Reynolds JC, Saul SM, et al. Barrett's metaplasia and adenocarcinoma of the esophagus in scleroderma. Am J Med. 1987;82:46-52.
26. Kozarek R. Complications of reflux esophagitis and their medical management. Gastroenterol Clin North Am. 1990;19:713-731.
27. Segel MC, Campbell WL, Medsger TA, et al. Systemic sclerosis (scleroderma) and esophageal adenocarcinoma: is increased patient screening necessary? Gastroenterology. 1985;89:486-488.
28. Ebert EC, Ruggiero FM, Seibold JR. Intestinal perforation: a common complication of scleroderma. Dig Dis Sci. 1997;42:549-553.
29. Lock G, Straub RH, Zeuner M, et al. Association of autonomic nervous dysfunction and esophageal dysmotility in systemic sclerosis. J Rheumatol. 1998;25:1330-1335.
30. Stacher G, Merio R, Budka C, et al. Cardiovascular autonomic function, autoantibodies, and esophageal motor activity in patients with systemic sclerosis and mixed connective tissue disease. J Rheumatol. 2000;27:692-697.
31. Dessein PH, Joffe BI, Metz RM, et al. Autonomic dysfunction in systemic sclerosis: sympathetic overactivity and instability. Am J Med. 1992;93:143-150.
32. Cohen S, Fisher R, Lipshutz W, et al. The pathogenesis of esophageal dysfunction in scleroderma and Raynaud's disease. J Clin Invest. 1972;51:2663-2668.
33. Belch JJ, Land D, Park RH, et al. Decreased oesophageal blood flow in patients with Raynaud's phenomenon. Br J Rheumatol. 1988; 27:426-430.
34. Hurwitz AL, Duranceau A, Postlethwait RW. Esophageal dysfunction and Raynaud's phenomenon in patients with scleroderma. Dig Dis Sci. 1976;21:601.
35. Klein HA, Wald A, Graham TO, et al. Comparative studies of esophageal function in systemic sclerosis. Gastroenterology. 1992;102:1551-1556.
36. Tsianos EV, Berecos C, Stavropoulos E, et al. The effects of peripheral cold exposure on oesophageal motility in patients with autoimmune rheumatic diseases and Raynaud's phenomenon. Clin Rheum. 1991;10:311-315.
37. Bestetti A, Carola F, Conciato L, et al. Esophageal scintigraphy with a semisolid meal to evaluate esophageal dysmotility in systemic sclerosis and Raynaud's phenomenon. J Nucl Med. 1999;40:77-84.
38. Mukhopadhyay AK, Graham DY. Esophageal motor dysfunction in systemic diseases. Arch Intern Med. 1976;136:583-587.
39. Baron M, Arzoumanian A. Radionuclide esophageal transit studies in progressive systemic sclerosis: an analysis of longitudinal data. J Rheumatol. 1991;18:1837-1840.
40. Garrett JM, Winkelmann RK, Schlegel JF, et al. Esophageal deterioration in scleroderma. Mayo Clin Proc. 1971;46:92-96.
41. Dantas RO, Meneghelli UG, Oliveira RB, et al. Esophageal dysfunction does not always worsen in systemic sclerosis. J Clin Gastroenterol. 1993;17:281-285.
42. Russell COH, Bright N, Buthpitiya G, et al. Oesophageal propulsive force and its relation to manometric pressure. Gut. 1992;33:727-732.
43. Creamer B, Anerson HA, Code CF. Esophageal motility in patients with scleroderma and related diseases. Gastroenterologia. 1956;86:763-775.
44. Kaufman HJ, Braverman IM, Spiro HM. Esophageal manometry in scleroderma. Scand J Gastroenterol. 1968;3:246-254.
45. Stentoft P, Hendel L, Aggestrup S. Esophageal manometry and pH-probe monitoring in the evaluation of gastroesophageal reflux in patients with progressive systemic sclerosis. Scand J Gastroenterol. 1987;22:499-504.
46. Yarze JC, Varga J, Stampfl D, et al. Esophageal function in systemic sclerosis: a prospective evaluation of motility and acid reflux in 36 patients. Am J Gastroenterol. 1993;88:870-876.
47. Johnson DA, Drane WE, Curran J, et al. Pulmonary disease in progressive systemic sclerosis: a complication of gastroesophageal reflux and occult aspiration? Arch Intern Med. 1989;149:589-593.
48. Kraus A, Alarcon-Segovia D. Air esophagogram and intestinal pseudoocclusion in a patient with scleroderma. J Rheumatol. 1991;18:897-899.
49. Olive A, Juncosa S, Evison G, et al. Air in the oesophagus: a sign of oesophageal involvement in systemic sclerosis. Clin Rheumatol. 1995;14:319-321.
50. Weihrauch TR, Korting GW. Manometric assessment of oesophageal involvement in progressive systemic sclerosis, morphoea, and Raynaud's disease. Br J Dermatol. 1992;107:325-332.
51. Bassotti G, Battaglia E, Debernardi V, et al. Esophageal dysfunction in scleroderma: relationship with disease subsets. Arthritis Rheum. 1997;40:2252-2259.
52. Marie I, Dominique S, Levesque H, et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Care Res. 2001;45:346-354.
53. Villadsen GE, Storkholm JH, Hendel L, et al. Impedance planimetric characterization of esophagus in systemic sclerosis patients with severe involvement of esophagus. Dig Dis Sci. 1997;42:2317-2326.
54. Tutuian R, Castell DO. Combined multichannel intraluminal impedance and manometry clarifies esophageal function abnormalities: study in 350 patients. Am J Gastroenterol. 2004;99:1011-1019.
55. Miller LS, Liu J-B, Klenn PJ, et al. Endoluminal ultrasonography of the distal esophagus in systemic sclerosis. Gastroenterology. 1993;105:31-39.
56. Cameron AJ, Malcolm A, Prather CM, et al. Videoendoscopic diagnosis of esophageal motility disorders. Gastrointest Endosc. 1999;49:62-69.
57. Troshinsky MB, Kane GC, Varga J, et al. Pulmonary function and gastroesophageal reflux in systemic sclerosis. Ann Int Med. 1994;121:6-10.
58. Weber P, Ganser G, Frosch M, et al. Twenty-four hour intraesophageal pH monitoring in children and adolescents with scleroderma and mixed connective tissue disease. J Rheumatol. 2000;27:2692-2695.
59. Zaninotto G, Peserico A, Costantini M, et al. Oesophageal motility and lower oesophageal sphincter competence in progressive systemic sclerosis and localized scleroderma. Scand J Gastroenterol. 1989;24:95-102.
60. Murphy JR, McNally P, Peller P, et al. Prolonged clearance is the primary abnormal reflux parameter in patients with progressive sclerosis and esophagitis. Dig Dis Sci. 1992;37:833-841.
61. Drane WE, Karvelis K, Johnson DA, et al. Progressive systemic sclerosis: radionuclide esophageal scintigraphy and manometry. Radiology. 1986;160:73-76.
62. Carola F, Bianchi PA, Basilisco G. Intraesophageal pH monitoring during acid infusion in patients with systemic sclerosis. Dig Dis Sci. 1999;44:1716-1720.
63. Basilisco G, Barbera R, Molgora M, et al. Acid clearance and oesophageal sensitivity in patients with progressive systemic sclerosis. Gut. 1993;34:1487-1491.
64. Baron M, Arzoumanian A. Radionuclide esophageal transit studies in progressive systemic sclerosis: an analysis of longitudinal data. J Rheumatol. 1991;18:1837-1840.
65. Edenbrandt L, Theander E, Hogstrom M, et al. Esophageal scintigraphy of systemic sclerosis. J Nucl Med. 1995;36:1533-1538.
66. Nakajima K, Kawano M, Kinuya K, et al. The diagnostic value of oesophageal transit scintigraphy for evaluating the severity of oesophageal complications in systemic sclerosis. Nucl Med Commun. 2004;25:375-381.
67. Davidson A, Russell C, Littlejohn O. Assessment of esophageal abnormalities in progressive systemic sclerosis using radionuclide transit. J Rheum. 1985;12:472-477.
68. Carette S, Lacourciere Y, Lavoie S, et al. Radionuclide esophageal transit in progressive systemic sclerosis. J Rheumatol. 1985;12:478-481.
69. Akesson A, Gustafson T, Wollheim F, et al. Esophageal dysfunction and radionuclide transit in progressive systemic sclerosis. Scand J Rheum. 1987;16:291-299.
70. Bryan C, Knight C, Black CM, et al. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum. 1999;42:2660-2665.
71. Denis P, Ducrotte P, Pasquis P, et al. Esophageal motility and pulmonary function in progressive systemic sclerosis. Respiration. 1981;42:21-24.
72. Lock G, Pfeifer M, Straub RH, et al. Association of esophageal dysfunction and pulmonary function impairment in systemic sclerosis. Am J Gastroenterol. 1998;93:341-345.
73. Kinuya K, Nakajima K, Kinuya S, et al. Esophageal hypomotility in systemic sclerosis: close relationship with pulmonary involvement. Ann Nucl Med. 2001;15:97-101.
74. Steen VD, Powell DL, Medsger TA. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988;31:196-203.
75. Gonzalez R, Storr M, Bloching H, et al. Autoantibody profile in progressive systemic sclerosis as markers for esophageal involvement. J Clin Gastroenterol. 2001;32:123-127.
76. Akesson A, Wollheim FA. Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. Br J Rheumatol. 1989;28:281-286.
77. Lock G, Holstege A, Lang B, et al. Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroenterol. 1997;92:763-771.
78. Lock G, Zeuner M, Straub RH, et al. Esophageal manometry in systemic sclerosis: screening procedure or confined to symptomatic patients? Rheum Int. 1997;17:61-66.
79. Akesson A, Akesson B, Gustafson T, et al. Gastrointestinal function in patients with progressive systemic sclerosis. Clin Rheum. 1985;4:441-448.
80. Geirsson AJ, Akesson A, Gustafson T, et al. Cineradiography identifies esophageal candidiasis in progressive systemic sclerosis. Clin Exp Rheumatol. 1989;7:43-46.
81. Hendel L, Svejgaard E, Walsoe I, et al. Esophageal candidiasis in progressive systemic sclerosis: occurrence, significance, and treatment with fluconazole. Scand J Gastroenterol. 1988;23:1182-1186.
82. Shoenut JP, Kerr P, Micflikier AB, et al. The effect of nasal CPAP on nocturnal reflux in patients with aperistaltic esophagus. Chest. 1994;106:738-741.
83. Kahan A, Bour B, Couturier D, et al. Nifedipine and esophageal dysfunction in progressive systemic sclerosis. A controlled manometric study. Arthritis Rheum. 1985;28:490-495.
84. Jean F, Aubert A, Bloch F, et al. Effects of diltiazem versus nifedipine on lower esophageal sphincter pressure in patients with progressive systemic sclerosis. Arthritis Rheum. 1986;29:1054-1055.
85. Shoenut JP, Wieler JA, Micflikier AB. The extent and pattern of gastro-oesophageal reflux in patients with scleroderma oesophagus: the effect of low-dose omeprazole. Aliment Pharmacol Ther. 1993;7:509-513.
86. Hendel L, Hage E, Hendel J, et al. Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis. Aliment Pharmacol Ther. 1992;6:565-577.
87. Hendel L, Aggestrup S, Stentoft P. Long-term ranitidine in progressive systemic sclerosis (scleroderma) with gastroesophageal reflux. Scand J Gastroenterol. 1986;21:799-805.
88. Petrokubi RJ, Jeffries GH. Cimetidine versus antacid in scleroderma with reflux esophagitis. A randomized double-blind controlled study. Gastroenterology. 1979;77:691-695.
89. Johnson DA, Drane WE, Curran J, et al. Metoclopramide response in patients with progressive systemic sclerosis. Effect on esophageal and gastric motility abnormalities. Arch Int Med. 1987;147:1597-1601.
90. Drane WE, Karvelis K, Johnson DA, et al. Scintigraphic detection of metoclopramide esophageal stimulation in progressive systemic sclerosis. J Nuc Med. 1987;28:810-815.
91. Ramirez-Mata M, Ibanez G, Alarcon-Segovia D. Stimulatory effect of metoclopramide on the esophagus and lower esophageal sphincter of patients with PSS. Arthritis Rheum. 1977;20:30.
92. Wang SJ, La JL, Chen DY, et al. Effects of cisapride on oesophageal transit of solids in patients with progressive systemic sclerosis. Clin Rheum. 2002;21:43-45.
93. Limburg AJ, Smit AJ, Kleibeuker JH. Effects of cisapride on the esophageal motor function of patients with progressive systemic sclerosis or mixed connective tissue disease. Digestion. 1991;49:156-160.
94. Kahan A, Chaussade S, Gaudric M, et al. The effect of cisapride on gastro-oesophageal dysfunction in systemic sclerosis: a controlled manometric study. Br J Clin Pharm. 1991;31:683-687.
95. Horowitz M, Maddern GJ, Maddox A, et al. Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis. Gastroenterology. 1987;93:311-315.
96. Hendel L, Stentoft P, Aggestrup S. The progress of oesophageal involvement in progressive systemic sclerosis during D-penicillamine treatment. Scand J Rheum. 1989;18:149-155.
97. Akesson A, Blom-Bulow B, Scheja A, et al. Long-term evaluation of penicillamine or cyclofenil in systemic sclerosis. Results from a two-year randomized study. Scand J Rheum. 1992;21:238-244.
98. Mansour KA, Malone CE. Surgery for scleroderma of the esophagus: a 12-year experience. Ann Thorac Surg. 1988;46:513-514.
99. Poirier NC, Taillefer R, Topart P, et al. Antireflux operations in patients with scleroderma. Ann Thorac Surg. 1994;58:66-72.
100. Orringer MB, Orringer JS, Dabich L, et al. Combined collis gastroplasty - fundoplication operations for scleroderma reflux esophagitis. Surgery. 1981;90:624-630.